Invesaro

Stocks Comparison

Park Ha Biological Technology vs Stepan: revenue, profit, margins and growth compared

Park Ha Biological Technology brought in $2.5M of revenue in fiscal 2025, Stepan $2.3B in fiscal 2025. Revenue changed by +6.0% at Park Ha Biological Technology and +7.0% at Stepan on the year before, so Stepan grew faster. Park Ha Biological Technology kept -965.0% of its revenue as net profit, Stepan 2.0%. Free cash flow was -$3K at Park Ha Biological Technology and $25.4M at Stepan.

Side by side, latest fiscal year

BYAHSCL
Fiscal year endedFY2025 (October 31, 2025)FY2025 (December 31, 2025)
Revenue$2.5M$2.3B
Revenue growth+6.0%+7.0%
Net income-$24.4M$46.9M
Net margin-965.0%2.0%
Free cash flow-$3K$25.4M
Free cash flow margin-0.1%1.1%
Earnings per share (diluted)-$41.38$2.05
Cash$3.8M$132.7M
Debtn/a$626.7M
Price to earningsn/a31.5
Market value$6.5M$1.5B
Dividend yieldn/a2.40%
Rank by revenue in sector#923 of 955 · Consumer discretionary#334 of 955 · Consumer discretionary

Over the years

Revenue
BYAH FY2022: $1.9MBYAH FY2024: $2.5MBYAH FY2024: $2.4MBYAH FY2025: $2.5MSCL FY2018: $2BSCL FY2019: $1.9BSCL FY2020: $1.9BSCL FY2021: $2.3BSCL FY2022: $2.8BSCL FY2023: $2.3BSCL FY2024: $2.2BSCL FY2025: $2.3BFY18FY19FY20FY21FY22FY23FY24FY25
BYAH $2.5MSCL $2.3B
Net income
BYAH FY2022: $191.3KBYAH FY2024: $852KBYAH FY2024: $478.6KBYAH FY2025: -$24.4MSCL FY2018: $111.1MSCL FY2019: $103.1MSCL FY2020: $126.8MSCL FY2021: $137.8MSCL FY2022: $147.2MSCL FY2023: $40.2MSCL FY2024: $50.4MSCL FY2025: $46.9MFY18FY19FY20FY21FY22FY23FY24FY25
BYAH -$24.4MSCL $46.9M
Net margin
BYAH FY2022: 10.0%BYAH FY2024: 34.6%BYAH FY2024: 20.1%BYAH FY2025: -965.0%SCL FY2018: 5.6%SCL FY2019: 5.5%SCL FY2020: 6.8%SCL FY2021: 5.9%SCL FY2022: 5.3%SCL FY2023: 1.7%SCL FY2024: 2.3%SCL FY2025: 2.0%FY18FY19FY20FY21FY22FY23FY24FY25
BYAH -965.0%SCL 2.0%
Revenue growth
BYAH FY2024: +28.1%BYAH FY2024: -3.1%BYAH FY2025: +6.0%SCL FY2019: -6.8%SCL FY2020: +0.6%SCL FY2021: +25.5%SCL FY2022: +18.2%SCL FY2023: -16.1%SCL FY2024: -6.3%SCL FY2025: +7.0%FY19FY20FY21FY22FY23FY24FY25
BYAH +6.0%SCL +7.0%
Free cash flow
BYAH FY2022: $1.4MBYAH FY2024: $103.9KBYAH FY2024: $874.9KBYAH FY2025: -$3KSCL FY2018: $84.5MSCL FY2019: $112.9MSCL FY2020: $109.4MSCL FY2021: -$122.3MSCL FY2022: -$140.8MSCL FY2023: -$85.5MSCL FY2024: $39.3MSCL FY2025: $25.4MFY18FY19FY20FY21FY22FY23FY24FY25
BYAH -$3KSCL $25.4M

Fiscal years as each company reports them; the two may end in different months.

Questions about Park Ha Biological Technology and Stepan

Which is bigger by revenue, Park Ha Biological Technology or Stepan?

Stepan is bigger by revenue: $2.3B in fiscal 2025, against $2.5M for Park Ha Biological Technology in fiscal 2025.

Which keeps more of its revenue as profit, Park Ha Biological Technology or Stepan?

Park Ha Biological Technology had a net margin of -965.0% in fiscal 2025; Stepan had 2.0% in fiscal 2025.

Which grew revenue faster, Park Ha Biological Technology or Stepan?

In their latest fiscal years revenue changed by +6.0% at Park Ha Biological Technology and +7.0% at Stepan.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies